Cargando...
Vedolizumab in the treatment of inflammatory bowel disease: evolving paradigms
Inflammatory bowel diseases, comprising Crohn’s disease (CD) and ulcerative colitis (UC), are chronic, relapsing and remitting immune-mediated inflammatory diseases affecting the gastrointestinal tract. Vedolizumab is the first licensed drug in a group of ‘gut-selective’ biological agents used to tr...
Gardado en:
| Publicado en: | Drugs Context |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
BioExcel Publishing Ltd
2020
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7055512/ https://ncbi.nlm.nih.gov/pubmed/32180822 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7573/dic.2019-10-2 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|